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Background. Antiretroviral compounds have been predominantly studied in human immunodeficiency virus
type 1 (HIV-1) subtype B, but only 10% of infections worldwide are caused by this subtype. The analysis of the
impact of different HIV subtypes on treatment outcome is important.
Methods. The effect of HIV-1 subtype B and non-B on the time to virological failure while taking combination
antiretroviral therapy (cART) was analyzed. Other studies that have addressed this question were limited by the
strong correlation between subtype and ethnicity. Our analysis was restricted to white patients from the Swiss HIV
Cohort Study who started cART between 1996 and 2009. Cox regression models were performed; adjusted for age,
sex, transmission category, first cART, baseline CD4 cell counts, and HIV RNA levels; and stratified for previous
mono/dual nucleoside reverse-transcriptase inhibitor treatment.
Results. Included in our study were 4729 patients infected with subtype B and 539 with non-B subtypes. The most
prevalent non-B subtypes were CRF02_AG (23.8%), A (23.4%), C (12.8%), and CRF01_AE (12.6%). The incidence
of virological failure was higher in patients with subtype B (4.3 failures/100 person-years; 95% confidence interval [CI],
4.0–4.5]) compared with non-B (1.8 failures/100 person-years; 95% CI, 1.4–2.4). Cox regression models confirmed
that patients infected with non-B subtypes had a lower risk of virological failure than those infected with subtype B
(univariable hazard ratio [HR], 0.39 [95% CI, .30–.52; P , .001]; multivariable HR, 0.68 [95% CI, .51–.91;
P 5 .009]). In particular, subtypes A and CRF02_AG revealed improved outcomes (multivariable HR, 0.54
[95% CI, .29–.98] and 0.39 [95% CI, .19–.79], respectively).
Conclusions. Improved virological outcomes among patients infected with non-B subtypes invalidate
concerns that these individuals are at a disadvantage because drugs have been designed primarily for subtype B
infections.
The human immunodeficiency virus (HIV) epidemic is
characterized by a high genotypic diversity with multiple
distinct viral subtypes and circulating recombinant
forms (CRFs) [1]. In Western countries, where most
antiretroviral compounds were designed and initially
tested, subtype B is predominant [2]. However, only
10% of global HIV infections are caused by subtype B.
The most prevalent subtype is C, which occurs mainly in
South Africa and East Africa [1].
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With the introduction of combination antiretroviral therapy
(cART), HIV/AIDS–related morbidity and mortality have been
markedly reduced [3, 4], but concerns exist that antiviral
susceptibility derived from studies with subtype B may not
be applicable to non-B infections [5]. It was suggested that
pretreatment genetic variation in HIV reverse transcriptase
and protease among different subtypes may affect treatment
response [6]. Studies in areas where non-B infections are pre-
dominant, mostly resource-limited settings, show promising
results; however, these data cannot be directly compared with
data derived from resource-rich settings. To reduce biases, it
is essential that intersubtype comparisons in single settings be
performed [7]. A few studies have been performed in Western
countries to analyze the effect of viral subtype on treatment
response [8–15]. However, all of these studies had limitations
and suffered from a short follow-up time, a small sample size,
or the strong correlation of ethnicity and subtype.
Our goal was to analyze the effects of HIV subtype on the viral
response after cART initiation in the Swiss HIV Cohort Study
(SHCS). The SHCS provides the unique opportunity to study
different subtypes in a single ethnic group, namely whites. This
is advantageous because HIV subtype and ethnicity are strongly
correlated and ethnicity is potentially associated with treatment
response and a different natural history of HIV [16–20]. Fur-
thermore, the study allows the exclusion of potential bias due
to different host genetic backgrounds [21].
METHODS
Study Population
The SHCS is a nationwide, multicenter, clinic-based cohort
with continuous enrollment and semiannual study visits [22].
The SHCS has been approved by the ethical committees of all
participating institutions, and written informed consent has
been obtained from all participants. Data from the SHCS up to
12 January 2011 were included. The present study was re-
stricted to white patients with known HIV subtype. Subtyping
was based on sequences from the SHCS drug resistance database
that are stored in SmartGene’s Integrated Database Network
System (version 3.6.0) [23]. Subtyping was performed using the
REGA 2 System. If the results were inconclusive, we repeated
subtyping using the Star analyzer (http://www.vgb.ucl.ac.uk/
starn.shtml) [24]. Sequences were excluded if the subtype
remained unequivocally undetermined.
Study Design
cART was defined as any antiretroviral therapy consisting
of $2 drug classes. Detection limits of HIV RNA assays
changed over the course of time (,400 copies/mL before
1999, ,50 copies/mL after 1999). Therefore, we performed
2 analyses with different definitions for viral suppression and
virological failure. Analysis A included patients who started
cART between 1 January 1996 and 31 December 2009. The
following definition of viral suppression was used: $1 viral
load below the detection limit (,400 copies/mL) between
days 90 and 365 after cART initiation. Virological failure was
defined as (1) 2 consecutive viral loads .1000 copies/mL after
previous suppression to ,400 copies/mL with uninterrupted
treatment, (2) 1 viral load .1000 copies/mL after previous
suppression to,400 copies/mL followed by a treatment change
or interruption, or (3) 1 viral load .1000 copies/mL after
180 days of treatment without previous suppression. If patients
changed the cART regimen when viral load was suppressed,
owing to toxicity, for example, the definition of virological
failure for (1) and (2) was adapted, and previous suppression to
,400 copies/mL was not required during the new treatment.
Analysis B included a subset of patients from analysis A.
Analysis B was limited to treatment-naive patients who started
cART between 1 January 1999 and 31 December 2009. In 1999,
all SHCS laboratories had changed their HIV RNA assays and
achieved detection limits of 50 copies/mL. Viral load meas-
urements with higher detection limits in this transition period
occurred rarely and were excluded from analysis. The definitions
of viral suppression and virological failure were adapted in
analysis B. Viral suppression was achieved when HIV RNA
levels were ,50 copies/mL. For the definition of virological
failure, the viral load limits in definitions (1), (2), and (3) were
changed as follows: The lower limit was ,50 copies/mL (in-
stead of ,400 copies/mL), and the upper limit was .500
copies/mL (instead of .1000 copies/mL).
Statistical Analysis
Baseline characteristics at cART initiation were analyzed using
the Fisher exact test (categorical variables) and the Wilcoxon
rank sum test (continuous variables). Baseline HIV RNA levels
and CD4 cell counts were considered when measured within
180 days before cART initiation. The time to viral suppression
was analyzed using univariable and multivariable logistic re-
gressions. Multivariable models were adjusted for sex, age,
transmission category, baseline HIV RNA level, baseline CD4
cell count, initial cART (unboosted protease inhibitor [PI],
ritonavir-boosted PI [PI/r], nonnucleoside reverse-transcriptase
inhibitor [NNRTI], or other), calendar period (analysis A, 1996–
1998, 1999–2003, 2004–2009; analysis B, 1999–2002, 2003–2006,
2007–2009), and previous treatment with mono/dual nucleo-
side reverse-transcriptase inhibitor (NRTI) therapy (only
analysis A). Continuous variables were categorized if likelihood-
ratio tests indicated significant departures from linearity.
Virological failure rates were analyzed using Kaplan–Meier
curves and log-rank tests. Additionally, univariable and multi-
variable Cox regression models were performed and adjusted
for the same potential confounders described above. The
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proportional hazard assumption was checked with Schoenfeld
residuals and by using graphical methods. Although pretreatment
with mono/dual NRTI therapy in analysis A did not satisfy the
proportional hazard assumption, we stratified the Cox models
for this variable. Colinearity was checked, and a variance in-
flation factor,3 was tolerated for regression models. All analyses
assumed intention to continue treatment and did not consider
treatment changes after the start of cART. Patient follow-up
was censored when the treatment was changed to a non-cART
regimen. Periods of treatment interruptions were subtracted
from the exposure time, and viral loads measured during
treatment interruptions were not considered for analysis.
Self-reported adherence has been measured since May 2003
in the SHCS and has been validated for treatment outcome [25].
We compared the lowest self-reported adherence between cART
initiation and censoring or virological failure. Statistical analyses
were performed with Stata 11 SE software (StataCorp). All
P values were 2 sided, and the level of significance was set at .05.
RESULTS
Study Population and Baseline Characteristics
Analysis A (cART start, 1996–2009) included 4729 of 5268
patients (89.8%) with subtype B infections and 539 (10.2%)
with non-B subtypes (Table 1). The most common non-B
subtypes were CRF02_AG (23.8%), A (23.4%), C (12.8%),
CRF01_AE (12.6%), and other (27.5%). Most patients infected
with ‘‘other’’ subtypes had a subtype F (29.1%; n5 43), subtype
G (28.4%; n 5 42), or subtype D (16.9%; n 5 25) infection.
CD4 cell counts at baseline tended to be lower in patients with
subtype B infection (median, 223 cells/lL; interquartile range
[IQR], 106–357) than in those with non-B infection (median,
243 cells/lL; IQR, 134–366; P 5 .088). The median log10 HIV
RNA level at baseline was similar in the 2 groups (subtype B,
4.7 copies/mL [IQR, 3.9–5.2]; non-B, 4.7 copies/mL [IQR,
3.9–5.3]). In analysis B (cART start, 1999–2009), 2166 of
2549 patients (85.0%) had subtype B infections and 383 had
non-B infections (15.0%). Most baseline characteristics were
similar to those in analysis A (Table 1).
First Combination Antiretroviral Therapy
In analysis A, 34.3% and 13.7% of patients infected with subtype
B or non-B, respectively, were pretreated withmono/dual NRTIs
(Table 2). The median year of cART initiation was earlier for
patients infected with subtype B (1999; IQR, 1997–2004) than
for those infections with non-B subtypes (2003; IQR, 1999–
2007), and patients with subtype B infections received un-
boosted PIs more frequently, (52.0% compared with 30.2% for
those with non-B infections). In analysis B, there was no dif-
ference in cART between groups (Table 2). The median years of
cART start were similar: 2004 (subtype B; IQR, 2001–2007) and
2005 (non-B subtypes; IQR, 2002–2007), respectively.
In both analyses, the most frequent NRTI combination was
lamivudine and zidovudine. Efavirenz was the most common
NNRTI, and lopinavir the most frequently used PI/r. Patients
treated with unboosted PIs received nelfinavir or indinavir most
frequently. Patients for whom treatment was not classified into
the categories of PI, PI/r, and NNRTI (analysis A, n 5 95;
analysis B, n5 35) often had combinations of PIs and NNRTIs
(analysis A, n 5 90/95; analysis B, n 5 33/35).
Time to Viral Suppression
In analysis A, 4433 of 4729 (93.7%) and 516 of 539 patients
(95.7%) infected with subtype B and non-B had $1 viral load
measured between day 90 and day 365 after cART initiation
(P 5 .070). Viral suppression was achieved in 3870 of 4433
(87.3%) and 481 of 516 (93.2%), respectively (P, .001). The
probability of achieving viral suppression was higher in patients
infected with non-B subtypes in the univariable logistic re-
gression model (odds ratio [OR], 2.0; 95% confidence interval
[CI], 1.4–2.8), but not in the multivariable model (OR, 1.2;
95% CI, .8–1.8). Results were similar in analysis B: 2076 of
2166 patients (95.8%) infected with subtype B and 375 of 285
(97.9%; P 5 .060) infected with non-B subtypes had a viral load
measured, of whom 1856 of 2076 (89.4%) and 338 of 375 patients
(90.1%) achieved viral suppression (P5 .715). Compared with
subtype B–infected patients, those infected with non-B sub-
types had a similar probability to achieve viral suppression
(univariable OR, 1.1 [95% CI, .8–1.6]; multivariable OR, 1.0
[.7–1.5]). When missing values were considered as treatment
failures, similar results were achieved in analyses A and B. No
specific non-B subtype had significantly different viral suppression
rates compared with subtype B (data not shown).
Time to Virological Failure
In analysis A, 5268 patients contributed 29 446 person-years of
follow-up. The incidence of virological failure was higher in
patients infected with subtype B (4.3 failures/100 person-years;
95% CI, 4.0–4.5) than in those infected with non-B subtypes
(1.8 failures/100 person-years; 1.4–2.4). Incidences of failure
were lower in analysis B, but patients infected with subtype B
also had a higher incidence of failure (2.6 failures/100 person-
years; 95% CI, 2.3–3.0) than those infected with non-B subtypes
(1.4 failures/100 person-years; .9–2.1); 2549 patients contributed
10 803 person-years of follow-up in analysis B.
Kaplan–Meier curves illustrate the time to virological failure
differentiated by type of treatment (Figure 1). As shown in Cox
regression models, the probability of experiencing a virological
failure was lower among patients infected with non-B subtypes
compared with subtype B (Table 3). In analysis A, the uni-
variable hazard ratio (HR) was 0.39 (95% CI, .30–.52; P, .001)
and the multivariable HR was 0.68 (95% CI, .51–.91; P5 .009).
Analysis B had similar results. The univariable HR was 0.54
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Table 1. Patients' Characteristics at Combination Antiretroviral Therapy Initiation
Characteristic
Analysis A (cART initiation, 1996–2009)
by subtype, no. (%) of patients
Analysis B (cART initiation, 1999–2009)
by subtype, no. (%) of patients
B Non-B P a 01_AE 02_AG A C Other P b B Non-B P a 01_AE 02_AG A C Other P b
Sex ,.001 ,.001 ,.001
Male 3768 (79.7) 363 (67.3) ,.001 43 (63.2) 121 (94.5) 60 (47.6) 47 (67.1) 93 (62.4) 1801 (83.2) 268 (70.0) 33 (61.1) 95 (97.9) 40 (48.8) 30 (68.2) 70 (66.0)
Female 961 (20.3) 176 (32.6) 25 (36.8) 7 (5.5) 66 (52.4) 21 (32.9) 56 (37.6) 365 (16.9) 115 (30.0) 21 (38.9) 2 (2.1) 42 (51.2) 14 (31.8) 36 (34.0)
Age, median
(IQR), years
47
(43–53)
50
(41–61)
,.001 47.5
(42–59.5)
51.5
(43–58)
56
(45–67)
51
(45–61)
45.5
(39.5–59.5)
,.001 45
(39–51)
50
(40–61)
,.001 46
(41–60)
52
(42–57)
55
(40–65)
51.5
(40–61)
46
(39–60)
,.001
Transmission
category
,.001 ,.001 ,.001 ,.001
HET 1082 (22.9) 388 (72.0) 58 (85.3) 84 (65.6) 101 (80.2) 50 (71.4) 96 (64.4) 533 (24.6) 265 (69.2) 44 (81.5) 63 (65.0) 62 (75.6) 30 (68.2) 66 (62.3)
MSM 2253 (47.6) 91 (16.9) 7 (10.3) 36 (28.1) 10 (7.9) 10 (14.3) 28 (18.8) 1147 (53.0) 76 (19.8) 7 (13.0) 32 (33.0) 6 (7.3) 7 (15.9) 24 (22.6)
IDU 1250 (26.4) 37 (6.9) 1 (1.5) 4 (3.1) 8 (6.3) 5 (7.1) 20 (13.4) 409 (18.9) 28 (7.3) 1 (1.9) 2 (2.1) 8 (9.8) 3 (6.8) 14 (13.2)
Other 144 (3.0) 23 (4.3) 2 (2.9) 4 (3.1) 7 (5.6) 5 (7.1) 5 (3.4) 77 (3.5) 14 (3.7) 2 (3.7) 0 (0.0) 6 (7.3) 4 (9.1) 2 (1.9)
CDC stage ,.001 ,.001 .044 .050
A 2536 (53.6) 366 (67.9) 47 (69.1) 93 (72.7) 79 (62.7) 50 (71.4) 98 (65.8) 1390 (64.2) 269 (70.2) 39 (72.2) 73 (75.3) 53 (64.6) 33 (75.0) 71 (67.0)
B 1255 (26.5) 101 (18.7) 16 (23.5) 13 (10.2) 25 (19.8) 14 (20.0) 34 (22.8) 422 (19.5) 68 (17.8) 12 (22.2) 8 (8.3) 16 (19.5) 8 (18.2) 24 (22.6)
C 938 (19.8) 72 (13.4) 5 (7.3) 22 (17.2) 22 (17.5) 6 (8.6) 17 (11.4) 354 (16.3) 46 (12.0) 3 (5.6) 16 (16.5) 13 (15.9) 3 (6.8) 11 (10.4)
CD4 count,
cells/lL
.081 .182 .284 .813
,200 1861 (44.4) 193 (40.2) 22 (37.9) 55 (48.3) 41 (36.9) 22 (34.9) 53 (39.3) 819 (42.5) 134 (39.3) 17 (37.0) 37 (43.5) 27 (37.0) 16 (41.0) 37 (37.8)
$200 2330 (55.6) 287 (59.8) 36 (62.1) 59 (51.8) 70 (63.1) 41 (65.1) 82 (60.7) 1108 (57.5) 207 (60.7) 29 (63.0) 48 (56.5) 46 (63.0) 23 (59.0) 61 (62.2)
NA 538 (11.4) 59 (10.9) .830 10 (14.7) 14 (10.9) 15 (11.9) 7 (10.0) 14 (9.4) .910 239 (11.0) 42 (11.0) 1.000 8 (14.8) 12 (12.4) 9 (11.0) 5 (11.4) 8 (7.5) .809
HIV-1 RNA level,
copies/mL
.884 .193 .528 .546
,10 000 1258 (28.5) 141 (27.4) 14 (22.2) 23 (18.6) 43 (35.5) 19 (28.4) 43 (30.5) 450 (21.5) 89 (24.1) 11 (21.6) 15 (16.1) 25 (30.9) 10 (23.8) 28 (27.2)
10 000–99 999 1583 (35.9) 187 (36.4) 25 (39.7) 47 (37.9) 44 (36.4) 27 (40.3) 45 (31.9) 764 (36.5) 132 (35.7) 20 (39.2) 36 (38.7) 27 (33.3) 17 (40.5) 32 (31.1)
$100 000 1571 (35.6) 186 (36.2) 24 (38.1) 54 (43.5) 34 (28.1) 21 (31.3) 53 (37.6) 882 (42.1) 149 (40.3) 20 (39.2) 42 (45.2) 29 (35.8) 15 (35.7) 43 (41.8)
NA 317 (6.7) 25 (4.6) .065 5 (7.3) 4 (3.1) 5 (4.0) 3 (4.3) 8 (5.4) .415 70 (3.2) 13 (3.4) .876 3 (5.6) 4 (4.1) 1 (1.2) 2 (4.5) 3 (2.8) .774
Abbreviations: cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HET, heterosexual; HIV-1, human immunodeficiency virus type 1; IDU, injection drug user; IQR, interquartile
range; MSM, men who have sex with men; NA, not available.
a Fisher exact test comparing subtype B and non-B infections.
b Fisher exact test comparing all particular subtypes.
1146
d
C
ID
2011:53
(1
D
ecem
b
er)
d
H
IV
/A
ID
S
(95% CI, .35–.82; P 5 .004) and the multivariable HR, 0.63
(.40–.96; P 5 .041). We also differentiated between the par-
ticular subtypes (Figure 2). The multivariable Cox regression
of analysis A showed that subtypes A (P 5 .042) and
CRF01_AG (P 5 .009) had significantly lower virological
failure rates than subtype B. No differences were found in
analysis B; however, sample sizes were small.
Although adherence to treatment is a potential bias, self-
reported adherence was similar between groups. In analysis A,
71.5% (subtype B) and 87.4% (non-B) of patients had $1
documented self-reported adherence between cART initiation
and the date of censoring or virological failure. Patients in-
fected with subtype B and non-B had similar adherence: 45.7%
and 49.9% never missed a dose, 27.7% and 28.2% missed
a maximum of 1 dose per month, and 26.6% and 21.9% missed
.1 dose per month (P 5 .073). In analysis B, 87.6% (subtype
B) and 93.5% (non-B) of patients had $1 documented self-
reported adherence. Results were similar to those in analysis
A. Other factors potentially associated with low adherence are
high rates of treatment changes and an increased number of
Table 2. First Combination Antiretroviral Therapy
Analysis A (cART initiation,
1996–2009) by subtype,
no. (%) of patients
Analysis B (cART initiation,
1999–2009) by subtype,
no. (%) of patients
Subtype B Non-B subtypes P a Subtype B Non-B subtypes P a
Year of cART initiation,
analysis A/analysis B
,.001 .001
1996–1998/1999–2002 2198 (46.5) 113 (21.0) 617 (28.5) 75 (19.6)
1999–2003/2003–2006 1164 (24.6) 165 (30.6) 660 (30.5) 138 (36.0)
2004–2009/2007–2009 1367 (28.9) 261 (48.4) 889 (41.0) 170 (44.4)
Pretreated with mono/dual NRTIs 1624 (34.3) 74 (13.7) ,.001 0 (0.0) 0 (0.0) –
Treatment included ,.001 .062
NNRTI 1035 (21.9) 177 (32.8) 863 (39.8) 157 (41.0)
PI/r 1143 (24.2) 197 (36.5) 896 (41.4) 171 (44.6)
PI 2458 (52.0) 163 (30.2) 373 (17.2) 54 (14.1)
Other 93 (2.0) 2 (0.4) 34 (1.6) 1 (0.3)
NRTI backbone ,.001 .087
ETC TDF 644 (13.6) 114 (21.1) 598 (27.6) 108 (28.2)
3TC AZT 1994 (42.2) 247 (45.8) 956 (44.1) 188 (49.1)
3TC D4T 857 (18.1) 44 (8.2) 114 (5.3) 11 (2.9)
D4T DDI 387 (8.2) 30 (5.6) 81 (3.7) 6 (1.6)
3TC ABC 172 (3.6) 31 (5.8) 152 (7.0) 29 (7.6)
3TC TDF 177 (3.7) 25 (4.6) 146 (6.7) 24 (6.3)
Other NRTIs 498 (10.5) 48 (8.9) 119 (5.5) 17 (4.4)
NNRTI .895 1.000
EFV 880 (85.5) 149 (84.2) 758 (87.8) 138 (87.9)
NVP 148 (14.3) 27 (15.3) 103 (11.9) 19 (12.1)
Other NNRTIs 7 (0.7) 1 (0.6) 2 (0.2) 0 (0.0)
PI/r ,.001 .083
LPV 625 (54.7) 136 (69.0) 589 (65.7) 127 (74.3)
ATV/r 224 (19.6) 37 (18.8) 195 (21.8) 33 (19.3)
IDV/r 92 (8.1) 7 (3.6) 70 (7.8) 6 (3.5)
Other PI/r 202 (17.7) 17 (8.6) 42 (4.7) 5 (2.9)
Unboosted PI ,.001 .629
NFV 910 (37.0) 93 (57.1) 307 (82.3) 47 (87.0)
IDV 949 (38.6) 42 (25.8) 31 (8.3) 5 (9.3)
RTV 402 (16.4) 12 (7.4) 2 (0.5) 0 (0.0)
Other PI 197 (8.0) 16 (9.8) 33 (1.1) 2 (3.7)
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; cART, combination antiretroviral therapy; D4T, stavudine; DDI,
didanosine; EFV, efavirenz; ETC, emtricitabine; IDV, indinavir; IDV/r, ritonavir-boosted IDV; LPV, lopinavir; NFV, nelfinavir; NNRTI, nonnucleoside reverse-
transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; PI/r, ritonavir-boosted PI; RTV, ritonavir; TDF,
tenofovir.
a Fisher exact test.
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treatment interruptions. Both factors were similar between
groups (data not shown).
To assess the robustness of the finding that non-B subtypes
have lower virological failure rates compared with subtype B,
we performed several sensitivity analyses. Kaplan–Meier curves
indicated that the effect of subtype was greatest in patients
treated with unboosted PIs. Excluding these patients from
analysis reduced the power of the model, but point estimates
of the Cox regression model were not altered substantially
(analysis A, univariable and multivariable HRs, 0.63 [95% CI,
.36–1.09] and 0.78 [.43–1.40] respectively; analysis B, univariable
and multivariable HRs, 0.64 [95% CI, .37–1.08] and 0.71
[.40–1.27]). In analysis A, results were similar if we excluded
patients who were treated with mono/dual NRTIs before cART
initiation (univariable HR, 0.46 [95% CI, .32–.65]; multivariable
HR, 0.58 [.40–.84]). If analyses A and B are limited to patients
with known CD4 cell and RNA values at baseline, univariable
HRs were 0.40 (95% CIs, .29–.53) and 0.56 (.36–.87),
respectively. Multivariable HRs were 0.71 (95% CI, .52–.97)
and 0.66 (.41–1.06), respectively. Results remained robust if we
censored the follow-up when a treatment interruption occurred
(analysis A, univariable and multivariable HRs, 0.38 [95% CI,
.28–.52] and 0.62 [.45–.86], respectively; analysis B, univariable
and multivariable HRs, 0.62 [.39–.99] and 0.69 [.42–1.13]). The
frequencies of HIV RNA measurements were comparable be-
tween patients infected with subtype B and those infected with
non-B subtypes, the median durations between measurements
were 96 (IQR, 79–119) and 92 (77–115) days in analysis A and
93 (79–117) and 91 (77–112) days in analysis B, respectively.
Because irregular or long durations without HIV RNA measure-
ments might bias the results, we censored patients’ follow-up
if the interval between 2 HIV RNA measurements was longer
than 180 days. Results remained robust (analysis A, univariable
and multivariable HRs, 0.38 [95% CI, .28–.50] and 0.68 [.50–.93];
analysis B, univariable and multivariable HRs, 0.56 [.37–.85]
and 0.63 [0.40–0.98]).
Figure 1. Kaplan–Meier curves differentiated by the first combination antiretroviral treatment (cART): unboosted protease inhibitor (PI), ritonavir-
boosted PI (PI/r), or nonnucleoside reverse-transcriptase inhibitor (NNRTI) show the time to virological failure. Analyses A and B included patients who
started cART in 1996–2009 or 1999–2009, respectively.
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Table 3. Cox Regression Models Analyzing the Time to Virological Failure
Analysis A (cART initiation, 1996–2009) Analysis B (cART initiation, 1999–2009)
Failures,
no.
At risk,
no.
Failures,
%
Univariable
HR (95% CI) P
Multivariablea
HR (95% CI) P
Failures,
no.
At risk,
no.
Failures,
%
Univariable
HR (95% CI) P
Multivariablea
HR (95% CI) P
Subtype
B 1140 4729 24.11 Reference Reference 240 2166 11.08 Reference Reference
Non-B 52 539 9.65 0.39 (.30–.52) ,.001 0.68 (.51–.91) .009 23 383 6.01 0.54 (.35–.82) .004 0.63 (.40–.98) .041
Age, per 10 years 1.09 (1.03–1.15) .003 0.92 (.86–.99) .021 0.97 (.86–1.09) .614 0.86 (.75–.99) .030
Sex
Male 946 4131 22.90 Reference Reference 215 2069 10.39 Reference Reference
Female 246 1137 21.64 0.90 (.78–1.03) .132 0.75 (.64–.87) ,.001 48 480 10.00 0.96 (.70–1.32) .808 0.76 (.54–1.07) .110
Transmission category ,.001 .355 ,.001 .099
MSM 496 2344 21.16 Reference Reference 101 1223 8.26 Reference Reference
HET 280 1470 19.05 0.86 (.75–1.00) 1.09 (.92–1.29) 81 798 10.15 1.17 (.88–1.57) 1.23 (.89–1.72)
IDU 387 1287 30.07 1.43 (1.25–1.63) 1.11 (.96–1.28) 72 437 16.48 2.05 (1.52–2.78) 1.52 (1.09–2.10)
Other 29 167 17.37 0.79 (.54–1.15) 0.87 (.60–1.27) 9 91 9.89 1.15 (.58–2.28) 1.40 (.70–2.80)
CD4 cell count, cells/lL ,.001 ,.001 .002 .055
,200 596 2054 29.02 Reference Reference 129 953 13.54 Reference Reference
$200 415 2617 15.86 0.53 (.47–.60) 0.62 (.54–.71) 100 1315 7.60 0.65 (.50–.84) 0.74 (.56–.97)
NA 181 597 30.32 1.06 (.90–1.25) 1.11 (.79–1.55) 34 281 12.10 1.04 (.71–1.52) 1.11 (.66–1.84)
HIV RNA level, copies/mL ,.001 ,.001 .063 .838
,10 000 252 1399 18.01 Reference Reference 45 539 8.35 Reference Reference
10 000–99 999 409 1770 23.11 1.36 (1.16–1.59) 1.65 (1.40–1.93) 85 896 9.49 1.09 (.76–1.57) 1.02 (.71–1.47)
$100 000 387 1757 22.03 1.24 (1.06–1.45) 1.59 (1.34–1.89) 117 1031 11.35 1.20 (.85–1.69) 1.13 (.79–1.62)
NA 144 342 42.11 2.39 (1.95–2.93) 1.32 (.90–1.93) 16 83 19.28 2.27 (1.28–4.02) 1.21 (.59–2.48)
Treatment ,.001 ,.001 ,.001 ,.001
PI 951 2621 36.28 Reference Reference 116 427 27.17 Reference Reference
PI/r 126 1340 9.40 0.27 (.23–.33) 0.66 (.54–.82) 70 1067 6.56 0.27 (.20–.37) 0.51 (.36–.73)
NNRTI 97 1212 8.00 0.22 (.18–.27) 0.61 (.47–.79) 69 1020 6.76 0.25 (.19–.34) 0.46 (.33–.65)
Other 18 95 18.95 0.53 (.33–.84) 0.71 (.44–1.15) 8 35 22.86 0.8 (.40–1.68) 0.94 (.45–1.95)
Year of cART initiation,
analysis A/analysis B
,.001 ,.001 ,.001 ,.001
1996–1998/1999–2002 899 2311 38.90 Reference Reference 164 692 23.70 Reference Reference
1999–2003/2003–2006 239 1329 17.98 0.43 (.37–.49) 0.73 (.60–.87) 65 798 8.15 0.33 (.25–.44) 0.48 (.34–.68)
2004–2009/2007–2009 54 1628 3.32 0.10 (.07–.13) 0.21 (.15–.30) 34 1059 3.21 0.19 (.13–.28) 0.30 (.19–.47)
Abbreviations: cART, combination antiretroviral treatment; CI, confidence interval; HET, heterosexual; HIV, human immunodeficiency virus; HR, hazard ratio; IDU, injection drug user; MSM, men who have sex with men;
NA, not available; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted PI.
a Multivariable analyses are adjusted for age, sex, transmission category, first cART, and baseline CD4 cell count and HIV RNA level. Analysis A is additionally stratified for previous mono/dual nucleoside reverse-
transcriptase inhibitor treatment.
H
IV
/A
ID
S
d
C
ID
2011:53
(1
D
ecem
b
er)
d
1149
The mode of transmission may also be a critical issue.
However, limiting the analysis to heterosexual patients did not
alter conclusions (analysis A, univariable and multivariable HRs,
0.41 [95% CI, .29–.59] and 0.61 [95% CI, .43–.88], respectively;
analysis B, univariable and multivariable HRs, 0.41 [.23–073 and
0.46 [.26–.83]). Moreover, adjusting the models for AIDS
(Centers for Disease Control and Prevention stage C) or strati-
fying analyses for year of treatment initiation confirmed find-
ings (data not shown). It was shown elsewhere that transmitted
antiretroviral resistance levels differ by subtype [26]. To assess
whether our results could be due to differential baseline resistance,
we performed a sensitivity analysis in a subset of patients in
whom genotypic resistance was determined before cART ini-
tiation (analysis A, n 5 3137 [59.6%]; analysis B, n 5 2121
[83.2%]). The number of patients with transmitted mutations
affecting the initial cART was slightly higher in the subtype B
group (analysis A, 5.4%; analysis B, 4.3%) compared with non-
B (each 2.4%). Hazard ratios of the multivariable Cox model for
the effect of viral subtype (analysis A, 0.66 [95% CI, .40–1.10];
analysis B, 0.80 [.48–1.33]) were not substantially altered when
information on transmitted resistance in multivariable models
was added (analysis A, 0.68 [.41–1.14]; analysis B, 0.83 [.50–1.39]).
DISCUSSION
We showed that white patients infected with HIV non-B sub-
types had an improved virological success rate during cART,
compared with patients infected with B subtype. In particular,
subtype A and CRF01_AG infections were associated with lower
virological failure rates. The time to viral suppression did not
differ between subtypes. In the last decade, a debate has arisen
as to whether antiretroviral compounds are less active against
non-B infections, because most antiretroviral drugs were de-
signed to be used against subtype B infections [7]. Our findings
indicate that these concerns are unwarranted.
We analyzed the impact of different HIV subtypes on treat-
ment response in a single ethnic group, that is, whites. Restricting
the analysis to a single ethnic group is advantageous and avoids
potential serious biases caused by the association of ethnicity
and subtype. Ethnic differences in host genetic factors influence
the natural history of HIV infection and the tolerability and
potentially the efficacy of cART [27]. Furthermore, cultural
differences between diverse ethnicities could influence viro-
logical outcome. The homogeneity of our cohort with regard to
genetic and cultural backgrounds allowed us to assess the im-
pact of viral subtypes on virological response independent of
ethnic variability [8, 16–19]. Although most patients infected
with non-B subtypes are nonwhite, the question of suscep-
tibility to cART among white patients infected with non-B
subtypes becomes more important, because the prevalence of
non-B infections is increasing in Western countries [26, 28].
Several in vitro studies were conducted to test the drug sus-
ceptibility of non-B subtypes. Overall, most non-B subtypes
possessed susceptibilities similar to those of subtype B (reviewed
in [6]). However, 1 study showed that CRF02_AG samples were
more susceptible to nelfinavir and ritonavir [29]. In our study,
the proportion of patients receiving these PIs was quite high,
which could partially explain our findings.
Our results differ from those of previously published obser-
vational studies [8–15, 18, 30]. However, most of these studies
were limited either by a small sample size, a short follow-up
time, missing adherence data, or the correlation of ethnicity and
transmission category with the HIV subtype. To date, Geretti
et al have published the largest study analyzing the effect of HIV
subtype on cART response. They found no significant inter-
subtype differences in treatment response [14]. However, owing
to the strong correlation of HIV subtype with ethnicity and
transmission group, they could not adjust their model for these
2 potential confounders [16, 17, 21]. In contrast, our study is
unbiased by ethnicity, and a sensitivity analysis clearly demon-
strated that results remained robust even when our analysis was
Figure 2. Univariable (solid circles) and multivariable (open squares)
Cox regression analyses comparing time to virological failure between
patients infected with different HIV subtypes and circulating recombinant
forms. Multivariable analyses are adjusted for age, sex, transmission
category, first combination antiretroviral therapy, and baseline CD4 cell
counts and HIV RNA levels. Analysis A is additionally stratified for
previous mono/dual nucleoside reverse-transcriptase inhibitor treatment.
Hazard ratios ,1 indicate a better virological response than in patients
infected with subtype B; 95% confidence intervals are indicated.
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limited to patients with heterosexual transmission. Further-
more, we used more restrictive criteria for virological failures.
Geretti et al did not ignore virological failures during treatment
interruptions in their main analysis, only in a sensitivity analysis
with highly reduced statistical power. However, both studies
exhibit a rather small number of virological failures among
patients infected with specific non-B subtypes. Contrary to that
of Geretti et al, our study comprised a higher proportion of
patients infected with subtype A, CRF01_AE, or CRF02_AG
and fewer patients infected with subtype C or D.
Although this is a large study addressing the question of
cART response among different HIV subtypes in a single ethnic
group, the sample sizes of some specific non-B subtypes were
small, and therefore the CIs for HRs remained wide. Larger cohort
collaborations will be necessary to strengthen our findings. In
our study, some baseline and treatment characteristics that are
predictive for response to cART (eg, treatment with unboosted
PI) differed between patients infected with subtype B and those
infected with non-B subtypes, especially in analysis A. How-
ever, results remained robust when we adjusted the models
for these factors. A sensitivity analysis confirmed that our
findings are not substantially biased by different resistance
levels of transmitted viruses. However, we cannot fully exclude
unsolved biases.
In conclusion, previous concerns that antiretroviral treatment
response might be hampered by development and testing of
antiretroviral compounds in resource-rich countries with high
subtype B prevalence are no longer tenable, and concerns that
non-B infections are less susceptible to cART are un-
warranted. In fact, patients infected with particular non-B
subtypes had lower virological failure rates than patients with
subtype B infections in Switzerland.
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